Guillermo Andrés

Guillermo Andrés

Auto-generated profile, based on publicly available information

Guillermo Andrés

Servicio de Urología, Hospital Universitario de Getafe, Universidad Europea de Madrid, Madrid, España

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 June 2014 in The Prostate
Verified
Journal Article
Closed access
PDF file
NANadia Ashour
Nadia Ashour
Javier C. AnguloJavier C. Angulo
Javier C. Angulo
GAGuillermo Andrés
Guillermo Andrés
RARaúl Alelú-Paz
Raúl Alelú-Paz
AGAna González-Corpas
Ana González-Corpas
SRSantiago Ropero
Santiago Ropero

21 December 2013 in Current Urology Reports
Verified
Journal Article
Closed access
PDF file
JGJavier Gonzalez
Javier Gonzalez
MEM. Esteban
M. Esteban
GAG. Andrés
G. Andrés
ELE. Linares
E. Linares
Juan Ignacio Martínez-SalamancaJuan Ignacio Martínez-Salamanca
Juan Ignacio Martínez-Salamanca

1 March 2016 in Journal of Urology
Verified
Journal Article
Closed access
Javier C. AnguloJavier C. Angulo
Javier C. Angulo
GAGuillermo Andrés
Guillermo Andrés
NANadia Ashour
Nadia Ashour
MSManuel Sánchez-Chapado
Manuel Sánchez-Chapado
Jose Ignacio LópezJose Ignacio López
Jose Ignacio López
SRSantiago Ropero
Santiago Ropero
Detection of DNA hypermethylation has emerged as a novel molecular biomarker for prostate cancer diagnosis and evaluation of prognosis. We sought to define whether a hypermethylation profile of patients with prostate cancer on androgen deprivation would predict castrate resistant prostate cancer. Genome-wide methylation analysis was performed using a methylation cancer panel in 10 normal prostates and 45 tumor samples from patients placed on androgen deprivation who were followed until castrate resistant disease developed. Castrate resistant disease was defined according to EAU (European Association of Urology) guideline criteria. Two pathologists reviewed the Gleason score, Ki-67 index and neuroendocrine differentiation. Hierarchical clustering analysis was performed and relationships with outcome were investigated by Cox regression and log rank analysis. We found 61 genes that were significantly hypermethylated in greater than 20% of tumors analyzed. Three clusters of patients were characterized by a DNA methylation profile, including 1 at risk for earlier castrate resistant disease (log rank p = 0.019) and specific mortality (log rank p = 0.002). Hypermethylation of ETV1 (HR 3.75) and ZNF215 (HR 2.89) predicted disease progression despite androgen deprivation. Hypermethylation of IRAK3 (HR 13.72), ZNF215 (HR 4.81) and SEPT9 (HR 7.64) were independent markers of prognosis. Prostate specific antigen greater than 25 ng/ml, Gleason pattern 5, Ki-67 index greater than 12% and metastasis at diagnosis also predicted a negative response to androgen deprivation. Study limitations included the retrospective design and limited number of cases. Epigenetic silencing of the mentioned genes could be novel molecular markers for the prognosis of advanced prostate cancer. It might predict castrate resistance during hormone deprivation and, thus, disease specific mortality. Gene hypermethylation is associated with disease progression in patients who receive hormone therapy. It could serve as a marker of the treatment response.

19 February 2021 in Neurourology and Urodynamics
Verified
Journal Article
Closed access
PDF file
ÁCÁngel García Cortés
Ángel García Cortés
JVJuan Colombás Vives
Juan Colombás Vives
CCCristina Gutiérrez Castañé
Cristina Gutiérrez Castañé
SRSantiago Chiva San Román
Santiago Chiva San Román
PLPablo Doménech López
Pablo Doménech López
JPJuan I. Pascual Piédrola
Juan I. Pascual Piédrola

1 February 2017 in Journal of Endourology
Verified
Journal Article
Closed access
HAHiury S. Andrade
Hiury S. Andrade
HZHomayoun Zargar
Homayoun Zargar
OAOktay Akca
Oktay Akca
OKOnder Kara
Onder Kara
PCPeter A. Caputo
Peter A. Caputo
JKJihad H. Kaouk
Jihad H. Kaouk
Purpose: To compare the oncological and functional outcomes of robotic partial nephrectomy (RPN) with radical nephrectomy (RN) in renal-cell carcinoma (RCC) cases with pT3a staging. Patients and Methods: A retrospective analysis of our IRB-approved nephrectomy database from 2005 to 2015 was performed. RPN and RN cases with confirmed RCC and pT3a staging were matched. Preoperative variables, functional, and oncological outcomes were compared between the groups, as well as Kaplan–Meier estimated overall survival (OS), cancer-specific survival (CSS), and recurrence-free survival (RFS). A multivariable Cox proportional hazards regression model for overall mortality rate was generated to evaluate hazard ratios (HRs) of potential risk factors. Results: Seventy patients with pT3a tumors composed each group. Preoperative variables were comparable between groups. The median follow-up time for the cohort was 20 (9–38) months and the renal function preservation was higher in the RPN group (86% vs 70%; p < 0.001). The estimated 3 years of OS (90% vs 84%; p = 0.42), CSS (94% vs 95%; p = 0.78), and RFS (95% vs. 100%; p = 0.06) were similar between RPN and RN groups, respectively. On multivariable Cox regression model, the presence of ≥2 aggressive tumor features was the only factor associated with increased risk of overall mortality rate (HR 4.01 95% confidence interval [1.13, 14.27)]; p = 0.03). Conclusion: Patients with localized pT3a RCC treated with RPN had similar short-term oncological and better renal functional outcomes compared with similar cases treated by RN. In the minimally invasive robotic surgery era, renal masses suspicious for pathological T3a disease should not be a deterring factor for performing nephron-sparing surgery when technically feasible by skilled surgeons.

1 November 2014 in Actas Urológicas Españolas
Verified
Journal Article
Closed access
FFF. Ramón de Fata
F. Ramón de Fata
AGA. García-Tello
A. García-Tello
GAG. Andrés
G. Andrés
Cristina RedondoCristina Redondo
Cristina Redondo
EME. Meilán
E. Meilán
Javier C. AnguloJavier C. Angulo
Javier C. Angulo